Research guide · Cognitive & Focus
Selank — research protocol
Synthetic heptapeptide studied for anxiolytic and cognitive support.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Synthetic heptapeptide
- Cognitive compound
- Sterile vial
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
Selank is a Russian-developed peptide studied for anxiety relief and mild focus support, also known as TP-7. It is approved in Russia for anxiety disorders and neurasthenia, but not FDA-approved in the United States.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Subcutaneous (Initiation) | 250-300 mcg | Once daily | Weeks 1-2 | Subcutaneous injection |
| Subcutaneous (Maintenance) | 400-500 mcg | Once daily | Weeks 3-4 | Subcutaneous injection |
| Subcutaneous (Repeat) | 300-500 mcg | Once daily | Weeks 9-12 | Subcutaneous injection |
| Intranasal (Standard course) | 600-2,700 mcg | 2-3 daily sprays | 14-21 days | Intranasal |
Cycle: SubQ: 4 weeks on, 4 weeks off. Intranasal: 14-21 days on, 1-3 weeks off.
Benefits and research observations: The calming effect builds over a few days, with a noticeable shift typically in 3-7 days. Russian trials report effect carryover for about a week after stopping.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Kozlovskii II, et al. Eksp Klin Farmakol, 2002.
- 2.Medvedev VE, et al. Zh Nevrol Psikhiatr, 2015.